Haemophilus Influenza type b (Hib)

Age Indications for Hib Vaccines (no doses prior to age 6 weeks)

ActHIB® (sanofi pasteur): for aged 2 months and older
PedvaxHiB® (Merck): for aged 2 months and older
Hiberix (Novartis): Last dose for age 15 months through 59 months

Indications for Use and Schedule

- Primary Series
  - ActHIB (4-dose series): a 3 dose primary series at 2, 4 & 6 months & booster dose at 12-15 months
  - PedvaxHiB (3-dose series): a 2-dose primary series at 2, 4 months & booster dose at 12-15 months

-Delayed Vaccination Schedule:
  - Children starting late may not need entire 3-4 dose series
  - Number of doses child requires depends on current age
  - All children 15-59 months of age need at least one dose

Minimum age and intervals –
- 6 weeks with the exception of Hiberix, the conjugate Hib vaccines are interchangeable
- 4 weeks between primary series doses
- 8 weeks between booster dose and previous dose

Hib Vaccine Schedule Based on Age at Time of First Dose (review chart below)

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>AGE AT 1ST DOSE (MONTHS)</th>
<th>PRIMARY SERIES</th>
<th>BOOSTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>ActHIB®</td>
<td>2-6</td>
<td>3 DOSES, 2 MONTHS APART</td>
<td>12-15 MONTHS**</td>
</tr>
<tr>
<td>4-dose series</td>
<td>7-11</td>
<td>2 DOSES, 2 MONTHS APART</td>
<td>12-15 MONTHS**</td>
</tr>
<tr>
<td>Note: Hib component of</td>
<td></td>
<td>1 DOSE</td>
<td>2 MONTHS LATER</td>
</tr>
<tr>
<td>Pentacel® (DTaP-IPV/Hib)</td>
<td>12-14</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15-59</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| PedvaxHiB®               | 2-6                      | 2 DOSES, 2 MONTHS APART | 12-15 MONTHS**        |
| 3-dose series            | 7-11                     | 2 DOSES, 2 MONTHS APART | 12-15 MONTHS**        |
| Note: Hib component of   |                          | 1 DOSE              | 2 MONTHS LATER         |
| Comvax® (HepB-Hib)      | 12-14                    |                     |                        |
|                          | 15-59                    |                     |                        |

*HIBERIX IS APPROVED ONLY FOR THE LAST DOSE OF THE Hib SERIES AMONG CHILDREN 12 MONTHS AND OLDER

**AT LEAST 2 MONTHS AFTER PREVIOUS DOSE

- Follow a 3-dose schedule if PedvaxHiB® (Comvax®)® is given for both primary series doses. Any Hib brand (PedvaxHiB®, Comvax®, ActHIB® or Pentacel®) can then be used for the booster dose (at/after age 12 months)

- If at least one of the primary series doses is given using ActHIB®, Pentacel® or MenHibrix®, follow the 4-dose schedule

VACCINATION OF PERSONS WITH HIGH-RISK CONDITIONS:

- Children aged 12 through 59 months at high risk for Hib diseases are: asplenics (including sickle cell disease), chemotherapy recipients, immunoglobulin deficiency, complement component deficiencies, or HIV
  - If no doses or only 1 dose of Hib vaccine given before 12 months of age, give 2 doses of Hib vaccine separated by 8 weeks
  - If 2 or more doses of Hib vaccine given before 12 months of age, give 1 dose of Hib vaccine 8 weeks later
- If no history of at least one previous dose, for persons:
  - Aged 165 months or older who are having elective splenectomy, give 1 dose of Hib vaccine at least 14 days prior to surgery
  - Aged 5 years & older who are asplenic (including sickle cell disease): give 1 dose of Hib vaccine
  - Aged 5 through 18 years, who have HIV infection, give 1 dose of Hib vaccine

NOTE: Due to low risk of Hib infection, adults aged 19 years & older with HIV are not recommended for Hib vaccine

- Persons who have had hematopoietic stem cell transplant (HSCT), regardless of their Hib vaccine history, should be revaccinated with 3 doses of Hib vaccine, 6 to 12 months after successful transplant; doses should be at least 4 weeks apart

MenHibrix® (Hib-MenCY)

- Intended only for infants 6 weeks through 18 months who are at high risk for meningococcal disease and need routine Hib vaccine

- Further information on Hib-MenCY risk groups, vaccine schedule and catch-up guidance is included in the “Recommended Immunization Schedule for Persons age 0 through 18 years and Catch-Up Schedule” at http://www.cdc.gov/vaccines

CONTRAINDICATIONS - An anaphylactic (severe allergic) reaction to a prior dose or a component of the Hib vaccine

PRECAUTIONS - Moderate to severe acute illness with or without fever; Use caution when vaccinating latex-sensitive individuals since the vial stopper contains dry latex rubber that may cause allergic reactions

FURTHER POINTS

- Hib vaccine is not routinely given once a child is 5 years (after age 59 months)
- Administer ActHIB® within 24 hours after reconstitution and MenHibrix® within 30 minutes after reconstitution
- For children 5 years or younger, if Hib vaccine dose(s) receive within 14 days of the start of or during chemotherapy/radiation treatment, repeat doses at least 3 months after therapy completion


Adapted from the Michigan Department of Community Health October 2014